Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

I probably sing the praises of Vertex Pharmaceuticals (NASDAQ: VRTX) as much as I do for any stock. And for good reason. Vertex is an outlier among Nasdaq stocks in that it has delivered an ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

In the latest trading session, Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 2.5%, and the tech-heavy Nasdaq lost 4.31%. Coming into today, shares of the drugmaker had lost ...

Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 1.69%, and the tech-heavy Nasdaq lost 2.7%. The drugmaker's stock has climbed by 5.91% in the past month, exceeding the Medical ...

In the latest trading session, Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq lost 0.53%. Heading into today, shares of the drugmaker had gained ...

Vertex noted that it will continue to work collaboratively ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in ...

In the latest trading session, Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 3.98%, and the tech-heavy Nasdaq lost 5.97%. Shares of the drugmaker witnessed a loss of 1.66% ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...